On Monday, Seres Therapeutics Inc (NASDAQ: MCRB) opened higher 5.31% from the last session, before settling in for the closing price of $0.55. Price fluctuations for MCRB have ranged from $0.54 to $2.05 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 386.36% over the last five years. Company’s average yearly earnings per share was noted 66.50% at the time writing. With a float of $124.68 million, this company’s outstanding shares have now reached $135.04 million.
The firm has a total of 233 workers. Let’s measure their productivity. In terms of profitability, gross margin is -10887.5%, operating margin of -221404.69%, and the pretax margin is -39804.69%.
Seres Therapeutics Inc (MCRB) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Seres Therapeutics Inc is 26.98%, while institutional ownership is 23.57%. The most recent insider transaction that took place on Oct 28 ’24, was worth 2,991. In this transaction an insider of this company sold 4,334 shares at a rate of $0.69, taking the stock ownership to the 30,423 shares. Before that another transaction happened on Oct 28 ’24, when Company’s insider sold 3,984 for $0.69, making the entire transaction worth $2,749. This insider now owns 75,885 shares in total.
Seres Therapeutics Inc (MCRB) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.28 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.57) by 0.29. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.2 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 66.50% per share during the next fiscal year.
Seres Therapeutics Inc (NASDAQ: MCRB) Trading Performance Indicators
Check out the current performance indicators for Seres Therapeutics Inc (MCRB). In the past quarter, the stock posted a quick ratio of 1.12. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1529.30.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.19, a number that is poised to hit -0.20 in the next quarter and is forecasted to reach -0.38 in one year’s time.
Technical Analysis of Seres Therapeutics Inc (MCRB)
Analysing the last 5-days average volume posted by the [Seres Therapeutics Inc, MCRB], we can find that recorded value of 3.56 million was lower than the volume posted last year of 4.32 million. As of the previous 9 days, the stock’s Stochastic %D was 5.79%. Additionally, its Average True Range was 0.07.
During the past 100 days, Seres Therapeutics Inc’s (MCRB) raw stochastic average was set at 3.87%, which indicates a significant decrease from 12.45% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 72.20% in the past 14 days, which was lower than the 110.89% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.8411, while its 200-day Moving Average is $0.9062. Now, the first resistance to watch is $0.6191. This is followed by the second major resistance level at $0.6592. The third major resistance level sits at $0.6985. If the price goes on to break the first support level at $0.5397, it is likely to go to the next support level at $0.5004. Should the price break the second support level, the third support level stands at $0.4603.
Seres Therapeutics Inc (NASDAQ: MCRB) Key Stats
There are currently 170,738K shares outstanding in the company with a market cap of 91.76 million. Presently, the company’s annual sales total 126,330 K according to its annual income of -113,720 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -40,130 K.
